Top

Breast Cancer Research and Treatment

Published in:

01-04-2011 | Letter to the Editor

Lymph node ratio, number of excised nodes and sentinel-node concepts in breast cancer

Authors: Nadia Peparini, Piero Chirletti

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Excerpt

To the Editor, …

Pepels MJ, Vestjens JHMJ, de Boer M et al. (2010) Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review. Breast Cancer Res Treat. doi:10.1007/s10549-010-1210-7

Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary lymph–node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933PubMedCrossRef

Veronesi U, Viale G, Paganelli G et al (2010) Sentinel node biopsy in breast cancer. Ten year results of a randomized controlled study. Ann Surg 251:595–600PubMedCrossRef

Moon HG, Han W, Noh DY (2010) Comparable survival between pN0 breast cancer patients undergoing sentinel node biopsy and extensive axillary dissection: a report from the Korean breast cancer society. J Clin Oncol 28:1692–1699PubMedCrossRef

Sanghani M, Balk EM, Cady B (2009) Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients. Cancer 115:1613–1620PubMedCrossRef

Vinh-Hung V, Verkooijen HM, Fioretta G et al (2009) Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol 27:1062–1068PubMedCrossRef

Danko ME, Bennett KM, Zhai J et al (2010) Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1788 patients with long-term follow-up. J Am Coll Surg 210:797–807PubMedCrossRef

Troung PT, Lesperance M, Li KH et al (2010) Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series. Ann Surg Oncol 17:2138–2146CrossRef

Axelsson CK, Durino M, Christansen PM et al (2009) Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer. Br J Surg 96:40–46PubMedCrossRef

10.

Wasif N, Maggard MA, Ko CY et al (2010) Underuse of axillary dissection for management of sentinel node micrometastases in breast cancer. Arch Surg 145:161–166PubMedCrossRef

11.

Straver ME, Meijnen P, van Tienhoven G et al (2010) Sentinel node identification rate and nodal involvement in the EORTC 10981–22023 AMAROS Trial. Ann Surg Oncol 17:1854–1861PubMedCrossRef

12.

Maaskant-Braat AJ, van de Poll-Franse LV, Voogd AC et al. (2010) Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Res Treat. doi: 10.1007s10549-010-1086-6 PubMed

13.

de Boer M, van Deurzen C, van Dijck JAAM et al (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361:653–663PubMedCrossRef

14.

Anderson SJ, Wapnir I, Dignam JJ et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473PubMedCrossRef

15.

Xing Y, Badgwell BD, Ross MI et al (2009) Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115:2505–2513PubMedCrossRef

Peparini N, Chirletti P (2010) Lymph node ratio, number of excised nodes and sentinel-node concepts in breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-1296-y PubMed

Pepels MJ, Vestjens JHMJ, de Boer M et al. (2010) Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review. Breast Cancer Res Treat doi:10.1007/s10549-010-1210-7

Woodward WA, Vinh-Hung V, Ueno NT et al (2006) Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 24:2910–2916PubMedCrossRef

Truong PT, Lesperance M, Li KH et al (2010) Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series. Ann Surg Oncol 17:2138–2146PubMedCrossRef

Vinh-Hung V, Verkooijen HM, Fioretta G et al (2009) Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol 27:1062–1068PubMedCrossRef

Axelsson CK, Durino M, Christansen PM et al (2009) Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer. Br J Surg 96:40–46PubMedCrossRef

Van Deurzen CH, de Boer M, Monninkhof EM et al (2008) Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst 100:1574–1580PubMedCrossRef

10.

de Boer M, van Deurzen C, van Dijck JAAM et al (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361:653–663PubMedCrossRef

11.

Pugliese M, Stempel M, Patil S et al (2010) The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer. Am J Surg 200:368–373PubMedCrossRef

12.

Leidenius MH, Vironen JH, Heikkilä PS et al (2010) Influence of isolated tumor cells in sentinel nodes on outcome in small, node-negative (pT1N0M0) breast cancer. Ann Surg Oncol 17:254–262PubMedCrossRef

13.

Hansen NM, Grube B, Ye X et al (2009) Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol 27:4679–4684PubMedCrossRef

14.

15.

Andersson Y, Frisell J, Sylvan M et al (2010) Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol 28:2868–2873PubMedCrossRef

16.

de Boer M, van Dijck JAAM, Bult P et al (2010) Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 102:410–425PubMedCrossRef

Title: Lymph node ratio, number of excised nodes and sentinel-node concepts in breast cancer
Authors: Nadia Peparini
Piero Chirletti
Publication date: 01-04-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1296-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2011

PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer

A combined analysis of genome-wide association studies in breast cancer

Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families

Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects

Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association

Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States

Keynote webinar | Spotlight on antibody–drug conjugates in cancer